These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 18831458)

  • 1. [Who should be responsible for the treatment of type 2 diabetes?].
    Ostgren CJ; Eliasson B
    Lakartidningen; 2008 Sep 3-9; 105(36):2432-3. PubMed ID: 18831458
    [No Abstract]   [Full Text] [Related]  

  • 2. Aggressive treatment of type 2 diabetes: a managed care consensus statement.
    Manag Care Interface; 2003; Suppl A():14-8. PubMed ID: 12564407
    [No Abstract]   [Full Text] [Related]  

  • 3. Appropriate advancement of type 2 diabetes therapy.
    Meneghini L; Kennedy L; Koff R; Kuritzky L; Leal S; Peterson K; Zamudio V
    J Fam Pract; 2007 Oct; 56(10 Suppl A):19A-29A; quiz 30A. PubMed ID: 17949601
    [No Abstract]   [Full Text] [Related]  

  • 4. [Prevention and early therapy play too minor a role in our health care system].
    Rothe HJ
    Med Klin (Munich); 2003 Oct; 98 Suppl 1():22-3. PubMed ID: 14694840
    [No Abstract]   [Full Text] [Related]  

  • 5. Type 2 diabetes.
    Draznin MB
    Adolesc Med State Art Rev; 2008 Dec; 19(3):498-506, x. PubMed ID: 19227388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implementing treatment guidelines for type 2 diabetes in primary care.
    Brunton S
    Postgrad Med; 2009 Mar; 121(2):125-38. PubMed ID: 19332971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Should future health-care costs be discounted? The case of diabetes in Australia.
    Scuffham PA
    Intern Med J; 2006 Mar; 36(3):148-9. PubMed ID: 16503948
    [No Abstract]   [Full Text] [Related]  

  • 8. Glycemic durability of monotherapy for diabetes.
    Gandhi GY; Montori VM
    N Engl J Med; 2007 Mar; 356(13):1379-80; author reply 1380. PubMed ID: 17402163
    [No Abstract]   [Full Text] [Related]  

  • 9. [The first inhalational insulin. Which patients really profit from it? (interview by Dr. D. Einecke)].
    Schumm-Draeger PM
    MMW Fortschr Med; 2007 Jan; 149(1-2):16-7. PubMed ID: 17632858
    [No Abstract]   [Full Text] [Related]  

  • 10. [Costs of antihyperglycemic drugs and consumables and treatment satisfaction in patients with type 2 diabetes. Results of the health care research study LIVE-DE (long-acting insulin glargine compared with NPH insulin in Germany)].
    Hauner H; Kohlmann T; Landgraf W; Holle R; Pirk O; Scholten T
    Dtsch Med Wochenschr; 2009 Jun; 134(23):1207-13. PubMed ID: 19472091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Editorial comment.
    Walson PD; Mullins CD; Lyles A; West JA
    Clin Ther; 2008 Oct; 30(10):1889. PubMed ID: 19014844
    [No Abstract]   [Full Text] [Related]  

  • 12. [DMP recommends only 4 antidiabetic drugs. When may different prescriptions be allowed?].
    MMW Fortschr Med; 2003 Sep; 145(38):62. PubMed ID: 14603690
    [No Abstract]   [Full Text] [Related]  

  • 13. [The German diabetes dilemma: DMP: insufficient management of the diabetic patient in general practice?].
    MMW Fortschr Med; 2005 Oct; 147(41):10. PubMed ID: 16270503
    [No Abstract]   [Full Text] [Related]  

  • 14. Primary care physicians and insulin initiation: multiple barriers, lack of knowledge or both?
    Jabbour S
    Int J Clin Pract; 2008 Jun; 62(6):845-7. PubMed ID: 18479275
    [No Abstract]   [Full Text] [Related]  

  • 15. [Guidelines for drug therapy in type II diabetes. French Agency for Health Safety in Health Products].
    Nephrologie; 2000; 21(2):75-7. PubMed ID: 10798208
    [No Abstract]   [Full Text] [Related]  

  • 16. Prescribing quality indicators of type 2 diabetes mellitus ambulatory care.
    Martirosyan L; Braspenning J; Denig P; de Grauw WJ; Bouma M; Storms F; Haaijer-Ruskamp FM
    Qual Saf Health Care; 2008 Oct; 17(5):318-23. PubMed ID: 18842968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Type 2 diabetes, is it just a case of hyperglycemia? Confusion between the interests of science, humanity and the economy].
    Ruiz J
    Rev Med Suisse; 2009 Jun; 5(206):1280-2. PubMed ID: 19579424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin U-500 in severe insulin resistance in type 2 diabetes mellitus.
    Crasto W; Jarvis J; Hackett E; Nayyar V; McNally PG; Davies MJ; Lawrence IG
    Postgrad Med J; 2009 Apr; 85(1002):219-22. PubMed ID: 19417173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resource utilisation and costs in patients with type 2 diabetes mellitus treated with insulin glargine or conventional basal insulin under real-world conditions in Germany: LIVE-SPP study.
    Schöffski O; Breitscheidel L; Benter U; Dippel FW; Müller M; Volk M; Pfohl M
    J Med Econ; 2008; 11(4):695-712. PubMed ID: 19450076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Basal insulin in discussion--clinical and health economics aspects].
    Middeke M
    Dtsch Med Wochenschr; 2008 Aug; 133 Suppl 4():S99; discussion S124-6. PubMed ID: 18686223
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.